1. Home
  2. FGEN vs COEP Comparison

FGEN vs COEP Comparison

Compare FGEN & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGEN
  • COEP
  • Stock Information
  • Founded
  • FGEN 1993
  • COEP 2017
  • Country
  • FGEN United States
  • COEP United States
  • Employees
  • FGEN N/A
  • COEP N/A
  • Industry
  • FGEN Biotechnology: Pharmaceutical Preparations
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FGEN Health Care
  • COEP Health Care
  • Exchange
  • FGEN Nasdaq
  • COEP Nasdaq
  • Market Cap
  • FGEN 34.5M
  • COEP 32.4M
  • IPO Year
  • FGEN 2014
  • COEP N/A
  • Fundamental
  • Price
  • FGEN $0.46
  • COEP $12.31
  • Analyst Decision
  • FGEN
  • COEP
  • Analyst Count
  • FGEN 0
  • COEP 0
  • Target Price
  • FGEN N/A
  • COEP N/A
  • AVG Volume (30 Days)
  • FGEN 727.9K
  • COEP 121.3K
  • Earning Date
  • FGEN 02-24-2025
  • COEP 03-25-2025
  • Dividend Yield
  • FGEN N/A
  • COEP N/A
  • EPS Growth
  • FGEN N/A
  • COEP N/A
  • EPS
  • FGEN N/A
  • COEP N/A
  • Revenue
  • FGEN $180,015,000.00
  • COEP N/A
  • Revenue This Year
  • FGEN $21.91
  • COEP N/A
  • Revenue Next Year
  • FGEN N/A
  • COEP N/A
  • P/E Ratio
  • FGEN N/A
  • COEP N/A
  • Revenue Growth
  • FGEN 16.15
  • COEP N/A
  • 52 Week Low
  • FGEN $0.18
  • COEP $2.31
  • 52 Week High
  • FGEN $2.80
  • COEP $13.70
  • Technical
  • Relative Strength Index (RSI)
  • FGEN 41.72
  • COEP 62.60
  • Support Level
  • FGEN $0.46
  • COEP $8.65
  • Resistance Level
  • FGEN $0.51
  • COEP $13.70
  • Average True Range (ATR)
  • FGEN 0.04
  • COEP 1.89
  • MACD
  • FGEN -0.01
  • COEP -0.21
  • Stochastic Oscillator
  • FGEN 6.59
  • COEP 72.48

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Share on Social Networks: